Aubagio Reduces Lesions in Children in Trial, but Relapse Data Troubled

Aubagio Reduces Lesions in Children in Trial, but Relapse Data Troubled

313407

Aubagio Reduces Lesions in Children in Trial, but Relapse Data Troubled

Aubagio (teriflunomide) failed to significantly reduce relapses in children with multiple sclerosis (MS), but two years of treatment decreased the number of brain lesions on MRI scans, according to the final results of the Phase 3 TERIKIDS clinical trial. Importantly, the lack of a signficantly lower relapse rate may have been due to the high number of participants switching to the open-label phase due to evidence of high disease activity on imaging scans, which reduced…

You must be logged in to read/download the full post.